Introduction
Haemorrhage is a recognized complication of anticoagulant therapy. It is usually seen in patients on long term oral therapy, when the incidence has been estimated to vary between 10 and 40%°. (Pastor, Resnick and Rodman, 1962) . The reported incidence during heparin therapy has varied from 4%/s (O'Sullivan et al., 1968) to 22% (Jick et al., 1968) . This may be related to poor anticoagulant control though Pitney, Pettit and Armstrong (1970) have shown an incidence of 7-6% of bleeding episodes in patients on carefully controlled heparin therapy. The onset of haemorrhage is commonly dramatic with external or obvious internal haemorrhage into gastro-intestinal or urino-genital tracts, skin or central nervous system. A more unusual presentation is occult retroperitoneal haemorrhage with no external signs of blood loss, presenting as a neurological lesion or with deep pain only. We present nine cases of retroperitoneal haemorrhage collected over 7 years from patients on anticoagulant therapy. Six of these, one of which proved fatal, were collected from a series of 139 patients on one medical unit who had received heparin for myocardial infarction. Case 9. A 56-year-old man admitted with myocardial infarction, was treated with intravenous heparin. A large right iliac haematoma appeared on the fourth day at an injection site. Although this swelling had not changed in size, he had a syncopal attack the following day. Thirty-six hours later, a painful swelling was noted in the right groin and he complained of paraesthesia in the distribution of the right femoral nerve. Active right hip movement was painful, and the right quadriceps power and right knee jerk were diminished with impaired sensation over the right knee area medially (his haemoglobin had dropped to 8-0 g). The heparin was stopped and he was transfused with 3 pints of blood. Over the next 48 hr, the knee jerk became stronger and the sensory deficit improved. Bruising of the right flank was obvious on the tenth day. It was felt that he had had a large retroperitoneal haematoma in addition to the subcutaneous thigh haematoma. The haematoma slowly resolved and he was discharged 2 weeks later fully mobile and without neurological abnormality.
Discussion
We have described nine cases of retroperitoneal haemorrhage, presenting with pain together with a nerve lesion in the majority, which developed in patients on anticoagulants. Six of the cases occurred in patients receiving short term intravenous heparin. Five of these developed a transient femoral or sciatic neuropathy which later recovered but the sixth patient died after extensive haemorrhage. This is the largest series of cases of nerve palsies related to heparin therapy which has been described.
Retroperitoneal haemorrhage has been less extensively documented than other anticoagulant complications. It was first noted in 1953 by Russek, who found it twice among 122 fatal cases of myocardial infarction receiving anticoagulants. Reiter (1966) described three cases presenting as an acute abdomen and similar cases were seen by Larsen et al. (1962 ), Hafner et al. (1962 and Hodin (1962) . Isolated cases presenting as an acute neurological lesion have been described by several authors, Pieri and Pinas (1964); Spurny et al. (1964); Strain (1964); Prill (1965) and Gallois, Dhers and Badarov (1967) , and more recently Lange (1966) collected four cases and Parkes and Kidner (1970) three cases presenting as femoral or sciatic nerve palsies. The majority of these cases occurred in patients on oral anticoagulants in contrast to the present series where the majority of the patients were on heparin.
The incidence of retroperitoneal haemorrhage in patients on heparin therapy has not been previously calculated. Pitney and Pettit (1970) found only one case in a series of seven bleeding episodes, the latter representing 7-6% of the patients on heparin. The present series was collected from 139 consecutive patients with myocardial infarction who received a 10-day course of intravenous heparin on the same wards over a period of 7 years, giving the much higher incidence of 4-3%4 of those at risk. The three subjects on oral anticoagulants were first seen by us because of their lesions and thus cannot be used to calculate an incidence in such patients.
The relationship between anticoagulant control and the occurrence of retroperitoneal haemorrhage is uncertain. Two of the patients on oral anticoagulants had poor control with a greatly raised prothrombin time at the time of presentation but it was only slightly elevated in the third case. The position is more obscure when the heparin series is considered. All these patients were receiving our current standard regimen for heparin which is 40,000 units in 24 hr given by continuous intravenous drip. No laboratory control was attempted although it is notable that this dose is in the middle of the weight-related dose range given by Pitney and Pettit (1970) . The latter authors assessed three separate methods of laboratory control and failed to find a satisfactory correlation between individual tests, none of which seemed to relate to the incidence of bleeding episodes. The time of bleeding, which in five of our six cases occurred between the seventh and tenth day of heparin therapy suggests that the dose was not grossly excessive. The sixth case developed haemorrhage after only 36 hr of treatment and this was the only fatal case.
The predilection for retroperitoneal haemorrhage in the heparinized patients is not easy to explain although intra-psoas haemorrhage is well recognized in haemophilia (Bullock and Fildes, 1911; Seddon, 1930; Tallroth, 1939; Aggeler and Lucia, 1944; Davidson et al., 1949 
